IL10 and neoplasm: In the TME, the IL-10 pathway aids immune evasion by inhibiting APC maturation and activity, limiting dendritic cells’ ability to present tumor antigens and hindering adaptive immune responses.327,328 Furthermore, IL-10 decreases the production of MHC class II and co-stimulatory molecules on APCs, impairing their ability to activate T cells.328 As a result, the anti-tumor-immune response is compromised, allowing tumor cells to escape immune detection and destruction.